ANAVEX LIFE SCIENCES CORP. AVXL
company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system ("CNS")
diseases with high unmet need. We analyze genomic data from clinical trials to identify biomarkers, which we use in the analysis of our
clinical trials.
treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases,
Last close
2.86
2026-09-04
Market cap
$265.1M
2026-06-30 share count
52-week range
2.25 - 10.40
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.54
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D | $37.6M | $41.8M | $43.7M | $37.9M | $33.0M | $25.2M | $22.3M | $13.3M | $10.7M | $7.3M |
| SG&A | $13.8M | $11.0M | $12.0M | $13.1M | $9.0M | $5.9M | $6.8M | $6.0M | $5.0M | $8.3M |
| Total operating expenses | $51.4M | $52.9M | $55.8M | $51.0M | $42.0M | -$31.1M | $29.1M | $19.3M | $15.7M | $15.6M |
| Operating income | -$51.4M | -$52.9M | -$55.8M | -$51.0M | -$42.0M | -$31.1M | — | — | — | — |
| Interest expense | $4.7M | $7.3M | $6.5M | $947.0K | $26.0K | $180.0K | $207.3K | $255.1K | $88.1K | $11.3K |
| Pre-tax income | -$46.4M | -$43.0M | -$47.5M | -$47.6M | -$37.6M | -$26.3M | -$26.2M | -$17.2M | -$13.4M | -$14.7M |
| Net income | -$46.4M | -$43.0M | -$47.5M | -$48.0M | -$37.9M | -$26.3M | -$26.3M | -$17.3M | -$13.5M | -$14.7M |
| EPS, basic | -0.54 | -0.52 | -0.60 | -0.62 | -0.54 | — | — | — | — | -0.42 |
| EPS, diluted | -0.54 | -0.52 | -0.60 | -0.62 | -0.54 | -0.45 | -0.54 | -0.39 | -0.33 | -0.42 |
| Shares, diluted (wtd. avg.) | $85.3M | $83.5M | $79.8M | $76.9M | $69.8M | — | — | — | — | $35.2M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $102.6M | $132.2M | $151.0M | $149.2M | $152.1M | $29.2M | $22.2M | $22.9M | $27.4M | $9.2M |
| Total current assets | — | — | — | — | — | — | $25.3M | $26.1M | $27.8M | $9.4M |
| Total assets | $103.8M | $135.6M | $154.4M | $152.7M | $161.6M | $34.5M | $25.3M | $26.2M | $27.8M | $9.5M |
| Accounts payable | $4.2M | $9.6M | $4.3M | $3.8M | $4.7M | $4.0M | $3.5M | $3.0M | $3.6M | $3.1M |
| Total current liabilities | — | — | — | — | — | — | $5.0M | $3.9M | $3.6M | $3.2M |
| Total liabilities | $8.9M | $15.3M | $12.5M | $10.2M | $10.8M | $7.3M | $5.0M | — | $3.6M | $3.2M |
| Retained earnings | -$382.4M | -$336.1M | -$293.1M | -$245.6M | -$197.6M | -$159.7M | -$133.4M | -$107.1M | -$89.8M | -$78.0M |
| Total equity | $94.9M | $120.3M | $141.9M | $142.5M | $150.8M | $27.2M | $20.3M | $22.3M | $25.9M | $6.3M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$39.0M | -$30.8M | -$27.8M | -$24.2M | -$30.4M | -$21.3M | -$18.5M | -$12.6M | -$9.0M | -$9.2M |
| Depreciation and amortisation | — | — | — | — | — | — | — | — | — | $1.3K |
| Stock-based compensation | $11.5M | $9.4M | $16.4M | $18.4M | $8.2M | $4.9M | $6.4M | $5.5M | $4.1M | $5.1M |
| Financing cash flow | $9.4M | $12.0M | $29.7M | $21.3M | $153.2M | $28.4M | $17.8M | $8.1M | $27.3M | $3.1M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001731122-26-001164.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $236.38B | 30.7x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $187.23B | 22.3x | 2.4% |
| MRNA | Moderna, Inc. | $58.11B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $45.01B | — | — |
| BIIB | BIOGEN INC. | $32.60B | 25.1x | 2.2% |
| SCNI | Scinai Immunotherapeutics Ltd. | $25.80B | — | 99.2% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $15.82B | 33.3x | 21.4% |
| EXEL | EXELIXIS, INC. | $14.62B | 21.2x | 7.0% |